AMOXICILLIN

Manufacturer Distributor Contents Indications GlaxoSmithKline Zuellig Amoxicillin trihydrate Treatment of susceptible infections including resp tract, skin & soft tissue, venereal, pelvic, severe systemic infections, actinomycoses, anthrax, biliary tract infections, bronchitis, gastroenteritis (including Salmonella enteritis, but not shigellosis), gonorrhea, Lyme disease, mouth infections, otitis media, pneumonia, typhoid & paratyphoidfever, UTI; dental abscess; prophylaxis of endocarditis, pneumococcal infection in spleen disorders; H. pylorieradication in PUD. Click to view Amoxil/Amoxil Forte detailed prescribing infomation Adult (including elderly) 250 mg tid, increase to 500 mg tid for more severe infections. Max: 6 g daily in divided doses. Severe or recurrent purulent infection of the resp tract 3 g bid. Simple acute UTI 3 g 10-12 hrly. Dental abscess 3 g bid w/ 8-hr interval. Gonorrhea 3 g as a single dose. Helicobacter eradication in PUD (duodenal & gastric) Omeprazole 40 mg daily + amoxicillin 1 g bid + clarithromycin 500 mg bid for 7 days or omeprazole 40 mg daily + amoxicillin 750 mg to 1 g bid + metronidazole 400 mg tid for 7 days. Childn 10 yr 125 mg tid, increase to 250 mg tid for more severe infections. Severe or recurrent acute otitis media 750 mg bid for 2 days. Adult & childn >40 kg w/ renal impairment 500 mg bid & 500 mg once daily for moderate & severe impairment respectively. Childn <40 kg w/ renal impairment Moderate impairment 15 mg/kg bid. Max: 500 mg bid. Severe impairment 15 mg/kg daily. Max: 500 mg/day. Prophylaxis of endocarditis Patients w/o general anesth in dental procedures Adult 3 g 1 hr prior to procedure, a 2nd dose given 6 hr thereafter if necessary; Childn <10yr the adult dose, <5 yr the adult dose. Patients w/ general anesth in dental procedures Adult Initially 3 g 4 hr prior to anesth, followed by another 3 g post-op. Click to view Amoxil/Amoxil Forte detailed prescribing infomation May be taken with or without food. May be taken w/ meals for better absorption & to reduce GI discomfort. View Amoxil/Amoxil Forte overdosage for action to be taken in the event of an overdose. Hypersensitivity to penicillins & cephalosporins. Click to view Amoxil/Amoxil Forte detailed prescribing infomation Infectious mononucleosis; prolonged use; renal impairment. Maintain adequate fluid intake & urinary output esp in high doses. False +ve in glucose test. Monitor the prothrombin time & INR. Pregnancy. Click to view Amoxil/Amoxil Forte detailed prescribing infomation Nausea, diarrhea, rash. View ADR Monitoring Website Probenecid, OCs, allopurinol. View more drug interactions with Amoxil/Amoxil Forte

Dosage

Administration Overdosage Contraindications Special Precautions

Adverse Drug Reactions Drug Interactions Pregnancy Category (US FDA)

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies st in women in the 1 trimester (and there is no evidence of a risk in later trimesters). Storage View Amoxil/Amoxil Forte storage conditions for details to ensure optimal shelf-life.

Mechanism of Action MIMS Class ATC Classification Poison Schedule Presentation/Packing

View Amoxil/Amoxil Forte mechanism of action for pharmacodynamics and pharmacokinetics details. Penicillins J01CA04 - amoxicillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections. Rx

Form Amoxil cap 250 mg Amoxil cap 500 mg Amoxil Ped oral drops 100 mg/mL Amoxil Forte syr 250 mg/5 mL Amoxil syr 125 mg/5 mL Manufacturer: GlaxoSmithKline

Photo

Packing/Price 100's (P764.10/box, P7.64/cap) 100's (P1337.20/box, P13.37/cap) 10 mL x 1's (P78.00/bottle) 20 mL x 1's 60 mL x 1's (P120.20/bottle) 60 mL x 1's (P87.00/bottle)

AMOXICILLIN-CLAVULANATE (Co-Amoxiclav) Amoclav

Manufacturer Distributor Contents Biomedis United Lab Co-amoxiclav (amoxicillin & clavulanic acid). Per 375 mg tab Amoxicillin 250 mg, clavulanic acid 125 mg. Per 625 mg tab Amoxicillin 500 mg, clavulanic acid 125 mg. Per 1 g tab Amoxicillin 875 mg, clavulanic acid 125 mg. Per 600 mg vial Amoxicillin 500 mg, clavulanic acid 100 mg. Per 1.2 g vial Amoxicillin 1 g, clavulanic acid 200 mg Lower resp tract infections, otitis media, sinusitis, skin & soft tissue infections, UTI, pre & postsurgical procedures, bone & joint, O & G infections, dental infections. Tab Adult & childn >12 yr Mild to moderate or in dental infection 375 mg tid. Severe infection 625 mg tid or 1 g bid.Inj Adult & childn >12 yr 1.2 g 8 hrly. Severe infection 6 hrly. 3 mth-12 yr 5/25 mg/kg 8 hrly, 0-3 mth 5/25 mg/kg 12 hrly. May increase to 8 hrly. May be taken with or without food. May be given w/o regard to meals. Best taken at the start of meals for better absorption & to reduce GI discomfort. History of penicillin hypersensitivity. Superinfections involving Pseudomonas or Candida. Pregnancy & lactation. Diarrhea, nausea, skin rashes & urticaria, vaginitis, abdominal discomfort, flatulence & headache. View ADR Monitoring Website Concomitant administration of probenecid may result in increased & prolonged blood levels of amoxicillin. Increased incidence of skin rashes w/ allopurinol. Do not give the drug together w/ disulfiram. View more drug interactions with Amoclav

Indications Dosage

Administration Contraindications Special Precautions Adverse Drug Reactions Drug Interactions

Pregnancy Category (US FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies st in women in the 1 trimester (and there is no evidence of a risk in later trimesters). MIMS Class ATC Classification Poison Schedule Presentation/Packing Penicillins J01CR02 - amoxicillin and enzyme inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections. Rx

Form Amoclav 1.2 g powd for inj

Packing/Price (vial) 1's (P549.29/vial)

Amoclav 600 mg powd for inj (vial) 1's (P326.44/vial) Amoclav 1 g tab Amoclav 375 mg tab 10's (P675.68/pack) 30's (P1132.48/pack)

Amoclav 625 mg tab Manufacturer: Biomedis

15's (P1696.58/pack)

2) Augmentin
Manufacturer Distributor Contents GlaxoSmithKline Zuellig Co-amoxiclav (amoxicillin & clavulanic acid). Per 375 mg tab Amoxicillin 250 mg, clavulanic acid 125 mg. Per 625 mg tab Amoxicillin 500 mg, clavulanic acid 125 mg. Per 1 g tab Amoxicillin 875 mg, clavulanic acid 125 mg. Per 5 mL of 156.25 mg susp Amoxicillin 125 mg, clavulanic acid 31.25 mg. Per 5 mL of 228.5 mg susp Amoxicillin 200 mg, clavulanic acid 28.5 mg. Per 5 mL of 312.5 mg susp Amoxicillin 250 mg, clavulanic acid 62.5 mg. Per 5 mL of 457 mg susp Amoxicillin 400 mg, clavulanic acid 57 mg. Per 600 mg vial Amoxicillin 500 mg, clavulanate K 100 mg.Per 1.2 g vial Amoxicillin 1 g, clavulanate K 200 mg Infections of upper & lower resp tract, GUT, skin & soft tissue, bone & joint, septic abortion, puerperal sepsis, intra-abdominal sepsis, dental infection (for oral prep), female genital infections, septicemia, peritonitis & post-surgical infections; prophylaxis against infections associated w/ major surgical procedure (for IV presentations). Click to view Augmentin detailed prescribing infomation Tab Adult Mild to moderate infections 375 mg tid or 625 mg bid-tid or 1 g bid. Severe infections 2 times 375 mg tid or 1-2 times 625 mg tid or 1 g bid-tid. Susp Childn Skin & soft tissue infection, recurrent tonsillitis 25-50 mg/kg/day tid. Otitis media, sinusitis, lower resp tract infection, UTI 50-75 mg/kg/day tid. Inj By intermittent IV infusion. Adult & childn >12 yr 1.2 g 8 hrly serious infections 6 hrly interval. Childn 3 mth-12 yr 30 mg/kg 8 hrly serious infection 6 hrly interval, 0-3 mth 30 mg/kg 12 hrly in premature infants & in full-term infants during perinatal period increasing to 8 hrly thereafter. Adult surgical prophylaxis Usual dose: 1.2 g IV at induction of anesth. High risk of infection: 3-4 doses of 1.2 g IV 24 hr period. Click to view Augmentin detailed prescribing infomation May be taken with or without food. May be given w/o regard to meals. Best taken at the start of meals for better absorption & to reduce GI discomfort. View Augmentin overdosage for action to be taken in the event of an overdose. Hypersensitivity to penicillins & cephalosporins or other allergen, possible cross sensitivity w/ other -lactams. History of penicillin-associated cholestatic jaundice/hepatic dysfunction. Click to view Augmentin detailed prescribing infomation Renal or hepatic impairment. Cholestatic jaundice. Infectious mononucleosis. Prolonged use. Care in patients on anticoagulants & Na-restricted diet. False +ve Coombs' test. Ensure adequate hydration esp w/ parenteral therapy or high doses. Pregnancy. Click to view Augmentin detailed prescribing infomation Diarrhea, indigestion, nausea, vomiting, candidiasis, rash. Rarely, pseudomembranous colitis, hepatitis, cholestatic jaundice, crystalluria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, reversible leukopenia, thrombocytopenia, hemolytic anaemia, CNS disturbances. View ADR Monitoring Website Probenecid, anticoagulants, OCs, allopurinol. Blood products, protein hydrolysates, IV lipid emulsions, aminoglycosides. View more drug interactions with Augmentin

Indications

Dosage

Administration Overdosage Contraindications

Special Precautions

Adverse Drug Reactions

Drug Interactions

Pregnancy Category (US FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there

are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies st in women in the 1 trimester (and there is no evidence of a risk in later trimesters). Caution For Usage Storage Description Mechanism of Action MIMS Class ATC Classification Poison Schedule Presentation/Packing For caution against possible variation of physical aspect of medicine... click to view Augmentin detailed prescribing infomation View Augmentin storage conditions for details to ensure optimal shelf-life. View Augmentin description for details of the chemical structure and excipients (inactive components). View Augmentin mechanism of action for pharmacodynamics and pharmacokinetics details. Penicillins J01CR02 - amoxicillin and enzyme inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections. Rx

Form Augmentin 156.25 mg/5 mL oral susp Augmentin 228.5 mg/5 mL oral susp Augmentin 312.5 mg/5 mL oral susp Augmentin 457 mg/5 mL oral susp Augmentin 1.2 g IV powd for inj Augmentin 600 mg IV powd for inj Augmentin 1 g tab Augmentin 375 mg tab Augmentin 625 mg tab

Photo

Packing/Price 60 mL x 1's (P179.50/bottle) 70 mL x 1's (P257.00/bottle) 60 mL x 1's (P306.00/bottle) 35 mL x 1's (P244.50/bottle) 70 mL x 1's (P439.50/bottle) (vial) 1's (P526.50/vial) (vial) 1's (P313.00/vial) 14's (P945.00/pack) 30's (P1131.34/pack)

CEFUROXIME Zinnat
Manufacturer Distributor Contents Indications GlaxoSmithKline Zuellig Pharma Cefuroxime axetil. Upper respiratory tract infections eg, ear, nose and throat infections ie,otitis media, sinusitis, tonsillitis and pharyngitis. Lower respiratory tract infections eg, pneumonia, acute bronchitis and acute exacerbations of chronic bronchitis. Genitourinary tract infections eg, pyelonephritis, cystitis and urethritis. Skin and soft-tissue infections eg, furunculosis, pyoderma andimpetigo. Gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis. Cefuroxime is also available as the sodium salt (Zinacef) for parenteral administration. This permits the use of sequential therapy with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated. Where appropriate, Zinnat is effective when used following initial parenteral Zinacef (cefuroxime sodium) in the treatment of pneumoniaand acute exacerbations of chronic bronchitis. The usual course of therapy is 7 days (Range 5-10 days). Zinnat should be taken after food for optimum absorption. Adults: Most Infections: 250 mg twice daily. Urinary Tract Infections: 125 mg twice daily. Mild to Moderate Lower Tract Infections eg, Bronchitis: 250 mg twice daily. More Severe Lower Tract Infections (or if pneumonia is suspected):500 mg twice daily. Pyelonephritis: 250 mg twice daily.

Dosage

Uncomplicated Gonorrhoea: Single dose of 1 g. Sequential Therapy: Pneumonia: Zinacef 1.5 g 2-3 times a day (IV or IM) for 48-72 hrs followed by Zinnat (cefuroxime axetil) 500 mg twice a day oral therapy for 7-10 days. Acute Exacerbations of Chronic Bronchitis: Zinacef 750 mg 2-3 times a day (IV or IM) for 48-72 hrs, followed by Zinnat 500 mg twice a day oral therapy for 5-10 days. Duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical status of the patient. Children: Most Infections: 125 mg twice daily, to a maximum of 250 mg daily. Children 2 years: Otitis Media or Where Appropriate, with More Severe Infections: 250 mg twice daily, to a maximum of 500 mg daily. Zinnat tablets should not be crushed and are therefore, unsuitable for treatment of patients eg, younger children, who cannot swallow tablets. In children, Zinnat oral suspension may be used. There is no experience of using Zinnat in children <3 months. There is no clinical trial data available on use of Zinnat in children <3 months. Infants and Children: It may be preferable to adjust dosage according to weight or age. The dose in infants and children 3 months to 12 years is 10 mg/kg twice daily for most infections, to a maximum of 250 mg daily. In otitis media or more severe infections, the recommended dose is 15 mg/kg twice daily to a maximum of 500 mg daily. The following tables, divided by age group and weight, serve as a guideline for simplified administration from measurement spoons (5 mL) for the 125 mg/5 mL multidose suspension and 125-mg single dose sachets. 10 mg/kg dosage for most infections. (See Table 1.)

Click on icon to see table/diagram 15 mg/kg dosage for otitis media and more serious infections. (See Table 2.)

Click on icon to see table/diagram To enhance compliance and improve the dosing accuracy in very young children, a dosing syringe can be supplied with a multidose bottle containing 50 mL of suspension. However, dosing in spoonfuls should be considered a more favourable option if the child is able to take the medication from the spoon. Administration: Directions for Constituting Suspension: Always shake the bottle vigorously before taking the medication. If desired, Zinnat suspension can be further diluted from multidose bottles in cold fruit juices, or milk drinks and should be taken immediately. Directions for Reconstituting Suspension in Multidose Bottles: Shake the bottle to loosen the granules. Remove the cap and the heat seal membrane. If the latter is damaged or not present, the product should be returned to the pharmacist. Add the total amount of water to the bottle as stated on its label. Replace the cap. Invert the bottle and rock vigorously (for about 15 sec). Turn the bottle into an upright position and shake vigorously. Directions for Reconstituting Suspension from Sachets: Empty granules from sachet into a glass. Add a small volume of water. Stir well and drink immediately. The reconstituted suspension or granules should not be mixed with hot liquids. Administration Should be taken with food. Take immediately after food.

Overdosage Contraindications Special Precautions

Overdosage of cephalosporins can cause cerebral irritations leading to convulsions. Serum levels of cefuroxime can be reduced by haemodialysis or peritoneal dialysis. Hypersensitivity to cephalosporins. Special care is indicated in patients who have experienced an allergic reaction to penicillins or other -lactams. As with other antibiotics, prolonged use of cefuroxime axetil may result in the overgrowth of nonsusceptible organisms (eg, Candida, Enterococci, Clostridium difficile), which may require interruption of treatment. Pseudomembranous colitis has been reported with the use of broad-spectrum antibiotics, therefore, it is important to consider its diagnosis in patients who develop serious diarrhoea during or after antibiotic use. With a sequential therapy regimen, the timing of change to oral therapy is determined by the severity of the infection, clinical status of the patient and susceptibility of the pathogens involved. If there is no clinical improvement within 72 hrs, then the parenteral course of treatment must be continued. The sucrose content of Zinnat suspension and granules (see Description) should be taken into account when treating diabetic patients and appropriate advice provided. Zinnat suspension contains aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria. Effects on the Ability to Drive or Operate Machinery: From the side effect profile of Zinnat, it is unlikely that treatment with this antibiotic will interfere with ability to drive or operate machinery. Use in pregnancy & lactation: There is no experimental evidence of embryopathic or teratogenic effects attributable to cefuroxime axetil but, as with all drugs, it should be administered with caution during the early months of pregnancy. Cefuroxime is excreted in human milk and consequently, caution should be exercised when Zinnat is administered to a nursing mother. Adverse reactions to cefuroxime axetil have been generally mild and transient in nature. As with other cephalosporins, there have been rare reports of erythema multiforme, StevensJohnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) and hypersensitivity reactions including skin rashes, urticaria, pruritus, drug fever, serum sickness, and very rarely, anaphylaxis. A small proportion of patients receiving Zinnat have experienced gastrointestinal disturbances, including diarrhoea, nausea and vomiting. As with other broad-spectrum antibiotics, there have been reports of pseudomembranous colitis. Headache has also been reported. Eosinophilia and transient increases of hepatic enzyme levels, [ALT (SGPT), AST (SGOT) and LDH] have been noted during Zinnat therapy. There have been rare reports of thrombocytopenia and leucopenia (sometimes profound). As with other cephalosporins, jaundice has been reported very rarely. Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs' test (which can interfere with cross-matching of blood) and very rarely, haemolytic anaemia. Click to view ADR Monitoring Website Drugs which reduce gastric acidity may result in a lower bioavailability of Zinnat compared with that of the fasting state and tend to cancel the effect of enhanced postprandial absorption. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. This antibiotic does not interfere in the alkaline picrate assay for creatinine. Incompatibilities: None.

Adverse Drug Reactions

Drug Interactions

View more drug interactions with Zinnat Pregnancy Category (US FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies st in women in the 1 trimester (and there is no evidence of a risk in later trimesters). Storage Store below 30C. The reconstituted suspension must be refrigerated between 2C and 8C. Shelf-Life: Tablet: 3 years. Suspension: 24 months for the unconstituted granules when stored below 30C. The reconstituted suspension when refrigerated between 2C and 8C can be kept up to 10 days. Zinnat suspension also contains the following excipients: Aspartame, xanthan gum, acesulfame potassium, povidone K30, stearic acid, sucrose, tutti-frutti flavour. It is provided as a dry, white to off-white granules. Each 125 mg/5 mL dose of suspension and 125 mg-sachet contains 3.062 g of sucrose. Zinnat is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most -lactamases and is active against a wide range of gram-positive and gramnegative organisms. It is indicated for the treatment of infections caused by sensitive bacteria. Microbiology: Cefuroxime axetil owes its in vivo bactericidal activity to the parent compound, cefuroxime. Cefuroxime is a well-characterised and effective antibacterial agent which has bactericidal activity against a wide range of common pathogens, including lactamase-producing strains. Cefuroxime has good stability to bacterial -lactamase and consequently, is active against many ampicillin-resistant or amoxycillin-resistant strains. The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins. Cefuroxime is usually active against the following organisms in vitro: Aerobes: GramNegative: Haemophilus influenzae (including ampicillin-resistant strains); Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae (including penicillinase- and non-penicillinase-producing strains); Escherichia coli; Klebsiella sp; Proteus mirabilis; Providencia sp; Proteus rettgeri. Aerobes: Gram-Positive: Staphylococcus aureus and Staphylococcus epidermidis (including penicillinase-producing strains but excluding methicillin-resistant strains), Streptococcus pyogenes (and other -haemolytic streptococci), Streptococcus pneumoniae, Streptococcus Group B (Streptococcus agalactiae). Anaerobes: Gram-positive and gram-negative cocci (includingPeptococcus sp and Peptostreptococcus sp); gram-positive bacilli (including Clostridium sp) and gramnegative bacilli (includingBacteroides sp and Fusobacterium sp); Propionibacterium sp. Other Organisms: Borrelia burgdorferi. The following organisms are not susceptible to cefuroxime: Clostridium difficile, Pseudomonas sp, and Campylobacter sp, Acinetobacter calcoaceticus, Listeria monocytogenes, Methicillin-resistant strains ofStaphylococcus aureus and Staphylococcus epidermidis, Legionella sp. Some strains of the following genera are not susceptible to cefuroxime:Enterococcus (Streptococcus) faecalis, Morganella morganii, Proteus vulgaris, Enterobacter sp, Citrobacter sp and Serratia sp, Bacteroides fragilis. Pharmacokinetics: After oral administration, cefuroxime axetil is slowly absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation.

Description

Mechanism of Action

Following administration of cefuroxime axetil tablets, peak serum levels (2.9 mg/L for a 125mg dose, 4.4 mg/L for a 250-mg dose, 7.7 mg/L for a 500-mg dose and 13.6 mg/L for a 1-g dose) occur approximately 2.4 hrs after dosing when taken with food. Optimum absorption occurs when it is administered after a meal. Peak serum levels (2-3 mg/L for a 125-mg dose, 4-6 mg/L for a 250-mg dose, 5-8 mg/L for a 500-mg dose and 9-14 mg/L for a 1-g dose) occur approximately 2-3 hrs after dosing when taken after food, unlike IV dosing which peaks immediately. The absorption of cefuroxime from the suspension is more prolonged compared with tablets, leading to later, lower peak serum levels and slightly reduced systemic bioavailability (4-17% less). Post peak levels, the serum half-life is between 1 and 1.5 hrs. Protein-binding has been variously stated as 33-50% depending on the methodology used. Cefuroxime is not metabolised and is excreted by glomerular filtration and tubular secretion. Concurrent administration of probenecid increases the area under the mean serum concentration-time curve (AUC) by 50%. Serum levels of cefuroxime are reduced by dialysis. Toxicology:Preclinical Safety Data: Animal toxicity studies indicated that cefuroxime axetil is of low toxicity with no significant findings. MIMS Class ATC Classification Poison Schedule Presentation/Packing Cephalosporins J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections. B Tab 125 mg (film-coated, white, capsule-shaped, engraved with 'GXES5' on one side and plain on the other) x 50's. 250 mg (film-coated, white, capsule-shaped, engraved with 'GXES7' on one side and plain on the other) x 10's, 50's. Oral susp 125 mg/5 mL (tutti-frutti flavour) x 50 mL.

CEFPODOXIME
Indications Dosage Listed in Dosage. Adult: PO Resp tract infections; UTI 100-200 mg 12 hrly. Skin infections 200-400 mg 12 hrly. Uncomplicated gonorrhoea200 mg as a single dose. Click to view cefpodoxime Dosage by Indications For action to be taken in the event of accidental overdose ... click to view cefpodoxime Hypersensitivity. History of allergy to penicillin; severe renal impairment; pregnancy and lactation. Anaphylactic shock; purpuric nephritis, skin rash, pruritus; diarrhoea, nausea, abdominal pain, vomiting. Potentially Fatal: Pseudomembranous colitis; nephrotoxicity. Antacids or H2-blockers may decrease the absorption of cefpodoxime. Probenecid inhibits renal excretion. Potentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide. Click to view more cefpodoxime Drug Interactions For caution against potential drug-food interactions ... click to view cefpodoxime For caution against possible drug interference in lab test results ... click to view cefpodoxime For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ...click to view cefpodoxime Cephalosporins

Overdosage Contraindications Special Precautions Adverse Drug Reactions Drug Interactions

Food Interaction Lab Interference Mechanism of Action MIMS Class

CEFPROZIL
Indications Dosage Administration Contraindications Special Precautions Adverse Drug Reactions Susceptible infections. Adult: PO 500 mg/day, may increase to 500 mg twice daily. Click to view cefprozil Dosage by Indications May be taken with or without food. (May be taken w/ meals to reduce GI discomfort.) Hypersensitivity. Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation. Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use. Potentially Fatal: Pseudomembranous colitis. Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogencontaining oral contraceptives. Click to view more cefprozil Drug Interactions For caution against possible drug interference in lab test results ... click to view cefprozil

Drug Interactions

Lab Interference Pregnancy Category (US FDA)

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies st in women in the 1 trimester (and there is no evidence of a risk in later trimesters). Mechanism of Action MIMS Class For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ...click to view cefprozil Cephalosporins

ATC Classification

J01DC10 - cefprozil ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.